Navigation Links
Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
Date:11/21/2008

CLINTON, N.J., Nov. 21 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that it has been named Private Company of the Year by the New Jersey Technology Council (NJTC), a 1,200-member non-profit organization that provides business support, networking opportunities, information and advocacy for technology companies and their leaders. Ikaria earned the award based on criteria including market leadership and unique product/service provision.

"We are delighted that the New Jersey Technology Council has recognized Ikaria for its leadership and innovation in critical care medicine," said Daniel Tasse, President and CEO of Ikaria. "This award is a testament to the hard work and pioneering spirit of our organization to deliver novel treatments for patients with unmet medical needs within the underserved critical care market."

Ikaria was honored at the NJTC Awards Gala on November 20, 2008, an annual black-tie event that attracts over 500 attendees. The NJTC Awards was founded in 1996 to publicly recognize and celebrate some of the most successful companies in the New Jersey technology community.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

1. INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.

    CONTACTS

    Samina Bari                                  Jason Rando/Jen Saunders
    Ikaria                                       The Ruth Group
    (908) 238-6372                               (646) 536-7025/7011
    samina.bari@ikaria.com                       jrando@theruthgroup.com
                                                 jsaunders@theruthgroup.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. American Board of Internal Medicine President Named to Alzheimers Study Group
3. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 4, 2017  A new tight-tolerance microextrusion medical ... highly-engineered materials, is being launched by Natvar, a ... developed in recent years to service a wide ... applications. More expensive materials such as glass and ... due to their ability to consistently hold tolerances. ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
(Date:5/2/2017)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... Med Tech Reimbursement Consulting AB that allows for ... Consulting AB,s proprietary market analyses through the MarketResearch.com website. ... the world easy access to complete product descriptions and ...
Breaking Medicine Technology:
(Date:5/24/2017)... Diego, California (PRWEB) , ... May 24, 2017 ... ... care through innovative medical image management and interpretation, has received U.S. Food and ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... recently completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) ... learning the latest advancements in his field by attending numerous CE courses each ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a trusted ... ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time visibility ... to the cloud to the edge. Through the new partnership, customers get the ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after actor, ... Television. “Informed” brings the public important topics from all aspects of life, and a ... and issues surrounding feet and ankles. , Podiatry is essential to people’s overall well-being, ...
Breaking Medicine News(10 mins):